As Immune Design Corp (IMDZ) Shares Rose, Shareholder Bvf INC Increased by $7.91 Million Its Stake

June 27, 2018 - By Leslie Harms

Big Money Sentiment decreased to 1.57 in 2018 Q1. It has change of 0.35, from 2017Q4’s 1.92. The ratio dropped due to IMDZ positioning: 11 sold and 12 reduced. 10 funds took stakes and 26 increased stakes. Investors holded 23.09 million in 2017Q4 but now own 21.61 million shares or 6.41% less. Tiaa Cref Investment Limited Liability holds 0% in Immune Design Corp. (NASDAQ:IMDZ) or 82,676 shs. stated it has 20,486 shs or 0% of all its holdings. 1.68M were accumulated by Bain Pub Equity Mngmt Limited Liability Com. Legal General Plc holds 5,795 shs or 0% of its capital. 1.24M are owned by Proquest Associate Iv Limited Liability Corp. Manufacturers Life Ins Comm The stated it has 931 shs or 0% of all its holdings. Jacobs Levy Equity Management holds 0% or 48,333 shs in its capital. Fmr Ltd, Massachusetts-based fund reported 1.18M shs. Meeder Asset reported 0% stake. Schwab Charles Mgmt Inc stated it has 0% of its capital in Immune Design Corp. (NASDAQ:IMDZ). Northern Trust holds 322,441 shs. Morgan Stanley accumulated 72,270 shs. Vanguard Gru stated it has 0% of its capital in Immune Design Corp. (NASDAQ:IMDZ). Voya Mgmt Limited Liability Company has invested 0% of its capital in Immune Design Corp. (NASDAQ:IMDZ). Wells Fargo & Com Mn stated it has 0% in Immune Design Corp. (NASDAQ:IMDZ).

IMDZ had 5 insider sales and 0 insider purchases since January 4, 2018. This’s net activity of $66,512. ter Meulen Jan Henrik had sold 1,986 shs worth $8,282. The insider Yurasov Sergey sold $2,816. Gombotz Wayne sold $8,282 worth of stock or 1,986 shs. Paya Carlos V sold $33,247 worth of stock or 7,970 shs.

The stake In Immune Design Corp (IMDZ) was rose held by Bvf Inc. According to 2018Q1 Securities and Exchange filling the reduction is 179.37%. The company’s stock rose 30.77% while stock markets declined as Bvf Inc bought 2.64M shares. At the end of 2018Q1, the hedge fund held 4.11M shares of the major pharmaceuticals company, valued at $13.55M, up from 1.47 million at the end of the previous reported quarter. Immune Design Corp has $202.13M MC. The stock decreased 4.55% or $0.2 during the last trading session, hitting $4.2.Currently Immune Design Corp. is downtrending after 47.53% change in last June 27, 2017. IMDZ has also 42,118 shares volume. IMDZ underperformed the S&P500 by 60.10%.

According to a filing Bvf Inc decreased its stake in Xenon Pharmaceuticals Inc by 2.87 million shares to 720,830 shares, valued at $3.53M in 2018Q1. The fund operates about $999.89M and $986.48M US Long portfolio. For a total of 6.93 million shares it reduced its holding in Cti Biopharma Corp by 1.67M shares in the quarter, and has cut its stake in Blueprint Medicines Corp.

More recent Immune Design Corp. (NASDAQ:IMDZ) news were released by Nasdaq.com, Seekingalpha.com and Nasdaq.com. The first one has “Immune Design to Host June 4 Cancer Immunotherapy Event in Chicago and Present at Jefferies 2018 Global …” as a title and was released on June 01, 2018. The next is “Is Immune Design Worth A Second Look?” on June 12, 2018. And last was released on June 25, 2018, called “Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the …”.

Immune Design Corp. (NASDAQ:IMDZ) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: